News Highlights – April 2021
05/05/2021
April followed the trend of March, with many advances in the liquid biopsy field. At the same time, there is an increasing interest in regulating the space, as the European Commission is moving forward with its appraisal of the impact of Grail’s acquisition by Illumina on the EU market.
On the diagnostic side, France has started changes in its testing funding system, with the inclusion of BCR-ABL into the formal reimbursement list, the first molecular biomarker that transitioned from the innovation fund into the statutory insurance system. Further advancements in diagnostics include Guardant Health agreement with Daiichi Sankyo to provide Guardant360 as the CDx for the treatment of NSCLC patients with trastuzumab-deruxtecan, and the Illumina partnership with Kartos Therapeutics to develop an NGS-based TP53 CDx.
As for the regulatory outcomes in April, nivolumab (BMS) got approval for renal cell carcinoma in combination with cabozantinib (EMA), for gastric and oesophageal cancers in combination with chemotherapy (FDA), and received a positive CHMP opinion recommending approval for malignant pleural mesothelioma. While nivolumab has made the news with multiple trials, including a combination with Candel’s CAN-2409 (oncolytic viral immunotherapy) for advanced gliomas, it also saw the rejection of NICE for the combo nivo+ipi for first line NSCLC based on cost-effectiveness.
In addition, both EMA and FDA approved GSK’s dostarlimab for the treatment of advanced or recurrent endometrial cancer, with Roche’s Ventana MMR RxDx immunohistochemistry panel as its CDx (FDA).
Summary of news (with links)
Regulatory decisions on Rx (18) |
- FDA approves Gilead’s Trodelvy® (sacituzumab govitecan) for metastatic triple-negative breast cancer. - https://www.gilead.com/news-and-press/press-room/press-releases/2021/4/fda-approves-trodelvy-the-first-treatment-for-metastatic-triplenegative-breast-cancer-shown-to-improve-progressionfree-survival-and-overall-surviv
- NICE 'no' for Opdivo/Yervoy lung cancer combo. - http://www.pharmatimes.com/news/nice_no_for_opdivoyervoy_lung_cancer_combo_1366600
- FDA grants accelerated approval to Trodelvy® for the treatment of metastatic urothelial cancer. - https://www.gilead.com/news-and-press/press-room/press-releases/2021/4/us-fda-grants-accelerated-approval-to-trodelvy-for-the-treatment-of-metastatic-urothelial-cancer
- Astrazeneca's Tagrisso approved in China for adjuvant treatment of EGFR-mutated NSCLC. - https://www.precisiononcologynews.com/regulatory-news-fda-approvals/astrazenecas-tagrisso-approved-china-adjuvant-treatment-egfr-mutated#.YHm_oBP7S_t
- Bristol Myers Squibb receives European Commission approval for Opdivo® (nivolumab) in combination with Cabometyx® (cabozantinib) as first-line treatment for patients with advanced renal cell carcinoma. - https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-in-Combination-with-Cabometyx-cabozantinib-as-First-Line-Treatment-for-Patients-with-Advanced-Renal-Cell-Carcinoma/default.aspx
- FDA approves Opdivo® (nivolumab) in combination with chemotherapy for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, regardless of PD-L1 expression status. - https://news.bms.com/news/corporate-financial/2021/U.S.-Food-and-Drug-Administration-Approves-Opdivo-nivolumab-in-Combination-with-Chemotherapy-for-Patients-with-Advanced-or-Metastatic-Gastric-Cancer-Gastroesophageal-Junction-Cancer-and-Esophageal-Adenocarcinoma/default.aspx
- Amgen's investigational targeted treatment bemarituzumab granted breakthrough therapy designation. - https://www.amgen.com/newsroom/press-releases/2021/04/amgens-investigational-targeted-treatment-bemarituzumab-granted-breakthrough-therapy-designation
- Seagen and Astellas announce FDA acceptance of two supplemental biologics license applications for Padcev® (enfortumab vedotin-ejfv) in locally advanced or metastatic urothelial cancer. - https://investor.seagen.com/press-releases/news-details/2021/Seagen-and-Astellas-Announce-U.S.-FDA-Acceptance-of-Two-Supplemental-Biologics-License-Applications-for-PADCEV-enfortumab-vedotin-ejfv-in-Locally-Advanced-or-Metastatic-Urothelial-Cancer/default.aspx
- European Commission approves GSK’s Jemperli (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer. - https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-gsk-s-jemperli-dostarlimab-the-first-anti-pd-1-therapy-approved-for-recurrent-or-advanced-endometrial-cancer/
- ADC Therapeutics announces FDA approval of Zynlonta™ (loncastuximab tesirine-lpyl) in relapsed or refractory diffuse large B-cell lymphoma. - https://ir.adctherapeutics.com/press-releases/press-release-details/2021/ADC-Therapeutics-Announces-FDA-Approval-of-ZYNLONTA-loncastuximab-tesirine-lpyl-in-Relapsed-or-Refractory-Diffuse-Large-B-Cell-Lymphoma/default.aspx
- Bristol Myers Squibb receives positive CHMP opinion for Onureg® (azacitidine tablets; CC-486) as frontline oral maintenance therapy for adults with acute myeloid leukemia in first remission. - https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Onureg-azacitidine-tablets-CC-486-as-Frontline-Oral-Maintenance-Therapy-for-Adults-with-Acute-Myeloid-Leukemia-in-First-Remission/default.aspx
- Bristol Myers Squibb receives positive CHMP opinion recommending approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) as first-line treatment for unresectable malignant pleural mesothelioma. - https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-First-Line-Treatment-for-Unresectable-Malignant-Pleural-Mesothelioma/default.aspx
- Tagrisso recommended for approval in the EU by CHMP for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer. - https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/tagrisso-adjuvant-receives-positive-chmp-opinion.html
- FDA grants priority review for new drug application for Takeda's mobocertinib (TAK-788) as a treatment for EGFR exon20 insertion+ metastatic NSCLC. - com/newsroom/newsreleases/2021/takeda-announces-u.s.-fda-grants-priority-review-for-new-drug-application-for-mobocertinib-tak-788-as-a-treatment-for-egfr-exon20-insertion-metastatic-non-small-cell-lung-cancer/
- FDA advisory committee votes in favor of maintaining accelerated approval of Genentech's Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer. - https://www.gene.com/media/press-releases/14907/2021-04-27/fda-advisory-committee-votes-in-favor-of
- FDA advisory committee votes in favor of maintaining accelerated approval of Genentech’s Tecentriq for previously untreated metastatic bladder cancer. - https://www.gene.com/media/press-releases/14908/2021-04-28/fda-advisory-committee-votes-in-favor-of
- Seagen and Genmab announce FDA filing acceptance for priority review of tisotumab vedotin biologics license application for patients with recurrent or metastatic cervical cancer. - https://investor.seagen.com/press-releases/news-details/2021/Seagen-and-Genmab-Announce-U.S.-FDA-Filing-Acceptance-for-Priority-Review-of-Tisotumab-Vedotin-Biologics-License-Application-for-Patients-with-Recurrent-or-Metastatic-Cervical-Cancer/default.aspx
- Enhertu® (trastuzumab deruxtecan) now available via the cancer drugs fund for the treatment of HER2 positive metastatic breast cancer. - https://www.businesswire.com/news/home/20210420005171/en
Dx approvals, market access and reimbursement (3) |
- Guardant Health receives New York State CLEP approval for Guardant Reveal blood test to detect and monitor residual disease in patients with early-stage cancer. - https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant-Health-Receives-New-York-State-CLEP-Approval-for-Guardant-Reveal-Blood-Test-to-Detect-and-Monitor-Residual-Disease-in-Patients-with-Early-Stage-Cancer/default.aspx
- Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy. - https://www.roche.com/media/releases/med-cor-2021-04-23.htm
- French Ministry of Health decision to modify the national price list for Healthcare Services. - https://www.eurofins-biomnis.com/wp-content/uploads/2021/04/JO078_010421.pdf
Latest diagnostic developments, investment and CDx deals (12) |
- City of Hope scientists develop a novel, non invasive liquid biopsy test for identification of lymph node metastasis in early-stage T1 colorectal cancer. - https://www.businesswire.com/news/home/20210421005225/en/City-of-Hope-Scientists-Develop-a-Novel-Noninvasive-Liquid-Biopsy-Test-for-Identification-of-Lymph-Node-Metastasis-in-Early-Stage-T1-Colorectal-Cancer
- Dermtech introduces PLAplus with improved sensitivity for early detection of melanoma. - https://www.businesswire.com/news/home/20210422005262/en
- Castle Biosciences presents data demonstrating DecisionDx-Melanoma as significant, independent predictor of recurrence in stage I cutaneous melanoma population. - https://ir.castlebiosciences.com/news-releases/news-release-details/castle-biosciences-presents-data-demonstrating-decisiondx-0
- Biodesix announces intent to launch liquid biopsy NGS test. - https://www.biodesix.com/newsroom/press-releases/biodesix-announces-intent-to-launch-liquid-biopsy-next-generation-sequencing-test-with-unprecedented-turnaround-time
- Genome Medical expands technology infrastructure to accelerate delivery of virtual genomic medicine. - https://resources.genomemedical.com/genome-medical-expands-technology-infrastructure-to-accelerate-delivery-of-virtual-genomic-medicine
- Armed with $55m in new funding, Nucleix to further invest in early-stage lung cancer Dx. - https://www.genomeweb.com/molecular-diagnostics/armed-55m-new-funding-nucleix-further-invest-early-stage-lung-cancer-dx#.YHaYhRP7S_s
- Volastra Therapeutics extends seed financing to $44 million to advance drug discovery programs to prevent cancer metastasis. - https://www.volastratx.com/volastra-therapeutics-extends-seed-financing-to-44-million-to-advance-drug-discovery-programs-to-prevent-cancer-metastasis/
- Veristat announces WindRose Health Investors as new investment partner. - https://www.veristat.com/news/veristat-announces-new-investment-partner-windrose-health-investors
- Nucleix secures $55 million funding led by RA Capital Management and additional prominent life science investors to advance Lung Epicheck® for early detection of lung cancer. - https://www.businesswire.com/news/home/20210407005322/en/
- Immunoscape raises $14m to advance deep immunomics platform for high-dimensional immune profiling and drug discovery. - https://immunoscape.com/immunoscape-raises-14m-to-advance-deep-immunomics-platform-for-high-dimensional-immune-profiling-and-drug-discovery/
- Deciphex led consortium secure €3m to develop novel prognostic tests to avoid overtreatment of cancer patients. - https://www.deciphex.com/deciphex-led-consortium-secure-3m-to-develop-novel-prognostic-tests-to-avoid-overtreatment-of-cancer.html
- KScan® Bioinformatics process receiving Japanese Patent No 6832294 for a method of assessing protein modification status and identifying biomarkers linked to cell signalling pathways.- https://www.linkedin.com/posts/kinomica_pharma-bioinformatics-proteomics-activity-6785522792042397696-LbI5; https://www.kinomica.com/
Clinical trials and drug development (16) |
- FDA accepts Investigational New Drug Application for Exelixis' XB002 in patients with advanced solid tumors. - https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-us-fda-accepts-investigational-new-drug
- Novocure announces FDA IDE approval and steering committee for KEYNOTE-B36 trial evaluating tumor treating fields together with pembrolizumab in non-small cell lung cancer. - https://www.novocure.com/novocure-announces-fda-ide-approval-and-steering-committee-for-keynote-b36-trial-evaluating-tumor-treating-fields-together-with-pembrolizumab-in-non-small-cell-lung-cancer/
- Bristol Myers Squibb announces Opdivo (nivolumab) plus chemotherapy and Opdivo plus Yervoy (ipilimumab) demonstrate superior survival benefit compared to chemotherapy in unresectable advanced or metastatic esophageal squamous cell carcinoma. - https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Announces-Opdivo-nivolumab-plus-Chemotherapy-and-Opdivo-plus-Yervoy-ipilimumab-Demonstrate-Superior-Survival-Benefit-Compared-to-Chemotherapy-in-Unresectable-Advanced-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspx
- DESTINY-CRC02 Phase 2 Trial of ENHERTU® initiated in patients with HER2-overexpressing advanced colorectal cancer. - https://www.daiichisankyo.com/files/news/pressrelease/pdf/202104/20210407_E.pdf
- LintonPharm announces authorization from China health authority (NMPA) to proceed with a Phase 1/2 trial evaluating catumaxomab for the treatment of non-muscle invasive bladder cancer. - http://www.lintonpharm.com/LINTONPHARM-ANNOUNCES-AUTHORIZATION-FROM?_l=en&article_id=14
- Mirati Therapeutics reports investigational adagrasib (MRTX849) preliminary data as well as initial MRTX1133 preclinical data. - https://www.biospace.com/article/releases/mirati-therapeutics-reports-investigational-adagrasib-mrtx849-preliminary-data-demonstrating-tolerability-and-durable-anti-tumor-activity-as-well-as-initial-mrtx1133-preclinical-data/
- Merck’s Keytruda® (pembrolizumab) demonstrated superior disease-free survival (DFS) compared with placebo as adjuvant therapy in patients with renal cell carcinoma (RCC) following surgery. - https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrated-superior-disease-free-survival-dfs-compared-with-placebo-as-adjuvant-therapy-in-patients-with-renal-cell-carcinoma-rcc-following-surgery/
- Bristol Myers Squibb announces Opdivo (nivolumab) plus chemotherapy and Opdivo plus Yervoy (ipilimumab) demonstrate superior survival benefit compared to chemotherapy in unresectable advanced or metastatic esophageal squamous cell carcinoma. - https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Announces-Opdivo-nivolumab-plus-Chemotherapy-and-Opdivo-plus-Yervoy-ipilimumab-Demonstrate-Superior-Survival-Benefit-Compared-to-Chemotherapy-in-Unresectable-Advanced-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspx
- SLFN11 expansion demonstrates potential as a predictive biomarker in SCLC. - https://www.targetedonc.com/view/slfn11-expansion-demonstrates-potential-as-a-predictive-biomarker-in-sclc
- Neoadjuvant Opdivo (nivolumab) plus chemotherapy significantly improves pathologic complete response in patients with resectable non-small cell lung cancer in phase 3 CheckMate -816 trial. - https://news.bms.com/news/corporate-financial/2021/Neoadjuvant-Opdivo-nivolumab-Plus-Chemotherapy-Significantly-Improves-Pathologic-Complete-Response-in-Patients-with-Resectable-Non-Small-Cell-Lung-Cancer-in-Phase-3-CheckMate--816-Trial/default.aspx
- Merck advances ATR inhibitor berzosertib in small cell lung cancer with new published data and initiation of Phase II trial with registrational intent. - https://www.merckgroup.com/en/news/berzosertib-cancer-cell.html
- Novocure announces update on Phase 3 pivotal LUNAR trial of tumor treating fields in non-small cell lung cancer. - https://www.novocure.com/novocure-announces-update-on-phase-3-pivotal-lunar-trial-of-tumor-treating-fields-in-non-small-cell-lung-cancer/
- Veracyte announces key milestone in companion diagnostics program with Acerta Pharma using LymphMark lymphoma subtyping test. - https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-key-milestone-companion-diagnostics-program
- Istari Oncology announces FDA clearance of IND to initiate LUMINOS-103: a basket trial evaluating the safety and efficacy for PVSRIPO in patients with advanced solid tumors. - https://istarioncology.com/istari-oncology-announces-fda-clearance-of-ind-to-initiate-luminos-103/
- Istari Oncology announces publication of Phase 1 data showing PVSRIPO immunotherapy leads to objective responses in patients with treatment-refractory melanoma. - https://istarioncology.com/istari-oncology-announces-publication-of-phase-1-data/
- Candel Therapeutics completes enrollment in Phase 1 clinical trial of CAN-2409 in combination with Opdivo® (nivolumab) for the treatment of high-grade gliomas. - https://www.candeltx.com/press-release/candel-therapeutics-completes-enrollment-in-phase-1-clinical-trial-of-can-2409/
Observational studies (7) |
- Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. - https://www.cell.com/cell/fulltext/S0092-8674(21)00294-4
- InterVenn’s glycoproteomic-based biomarker signature successfully predicts favorable outcomes in metastatic malignant melanoma patients treated with checkpoint inhibitors. - https://www.businesswire.com/news/home/20210412005237/en/InterVenn%E2%80%99s-Glycoproteomic-based-Biomarker-Signature-Successfully-Predicts-Favorable-Outcomes-in-Metastatic-Malignant-Melanoma-Patients-Treated-with-Checkpoint-Inhibitors
- Castle Biosciences announces prospective, multi-center publication demonstrating DecisionDx®-Melanoma as significant, independent predictor of patient outcomes in cutaneous melanoma. - https://ir.castlebiosciences.com/news-releases/news-release-details/castle-biosciences-announces-prospective-multi-center
- Castle Biosciences' i31-GEP artificial intelligence algorithm improves precision of sentinel lymph node positivity prediction in cutaneous melanoma. - https://ir.castlebiosciences.com/news-releases/news-release-details/late-breaking-new-independent-validation-study-1674-patients
- Sagasafe® technology utilized in new study of ESR1 mutations in breast cancer. - https://sagadiagnostics.com/sagasafe-technology-utilized-in-new-study-of-esr1-mutations-in-breast-cancer/
- Veracyte announces publication of study showing robust performance of Percepta GSC in improving lung cancer diagnosis. - https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-publication-study-showing-robust-performance
- Study shows Guardant Reveal™ Blood-Only liquid biopsy test predicts risk for colorectal cancer recurrence. - https://investors.guardanthealth.com/press-releases/press-releases/2021/Study-Shows-Guardant-Reveal-Blood-Only-Liquid-Biopsy-Test-Predicts-Risk-for-Colorectal-Cancer-Recurrence-with-Industry-Leading-Sensitivity/default.aspx
Merge and acquisitions (9) |
- Merck completes acquisition of Pandion Therapeutics. - https://www.merck.com/news/merck-completes-acquisition-of-pandion-therapeutics/
- Euformatics eyes global expansion in NGS Informatics. - https://www.genomeweb.com/informatics/euformatics-eyes-global-expansion-ngs-informatics#.YG1VwBP7S_s
- Acornmed selects Twist Bioscience technology to power next generation precision medicine tests. - https://www.biospace.com/article/releases/acornmed-selects-twist-bioscience-technology-to-power-next-generation-precision-medicine-tests/
- DiaSorin to acquire Luminex corporation for USD 37.00 per share or approximately USD 1.8 billion. - https://diasoringroup.com/sites/diasorincorp/files/allegati_pressrel/diasorin_to_acquire_luminex_corporation.pdf
- Tango Therapeutics and BCTG Acquisition Corp. announce merger agreement to create publicly listed precision medicine company focused on the next generation of targeted cancer therapies. - https://www.tangotx.com/press_releases/tango-therapeutics-and-bctg-acquisition-corp-announce-merger-agreement-to-create-publicly-listed-precision-medicine-company-focused-on-the-next-generation-of-targeted-cancer-therapies/
- Agilent completes acquisition of Resolution Bioscience, expands role in fast-growing NGS market for precision oncology. - https://www.agilent.com/about/newsroom/presrel/2021/15apr-gp21013.html
- Thermo Fisher Scientific to acquire PPD. - https://thermofisher.mediaroom.com/2021-04-15-Thermo-Fisher-Scientific-to-Acquire-PPD-Inc-a-Leading-Clinical-Research-Organization
- European Commission to assess proposed acquisition of Grail by Illumina. - https://ec.europa.eu/commission/presscorner/detail/en/mex_21_1846
- Amgen successfully completes acquisition of Five Prime Therapeutics. - https://www.amgen.com/newsroom/press-releases/2021/04/amgen-successfully-completes-acquisition-of-five-prime-therapeutics
Partnerships (22) |
- Volastra Therapeutics partners with Microsoft to advance metastatic cancer research. - https://www.volastratx.com/volastra-therapeutics-partners-with-microsoft-to-advance-metastatic-cancer-research/
- OncoDNA and myNEO join forces to unlock the power of mRNA therapeutics. - https://www.oncodna.com/en/company/activity/news-list/personalized-mRNA-vaccines-cancer-patients-myNEO/
- PsiOxus Therapeutics updates agreement with Bristol-Myers Squibb to advance their clinical stage immuno-oncology collaboration. - https://psioxus.com/psioxus-therapeutics-updates-agreement-with-bristol-myers-squibb-to-advance-their-clinical-stage-immuno-oncology-collaboration/
- TriSalus Life Sciences and MD Anderson announce strategic research collaboration to evaluate treatment of solid tumors. - https://trisaluslifesci.com/trisalus-life-sciences-and-md-anderson-announce-strategic-research-collaboration-to-evaluate-treatment-of-solid-tumors/
- Philips and Ibex Medical Analytics team to accelerate adoption of AI-powered digital pathology. - https://ibex-ai.com/press/philips-and-ibex/
- Biognosys announces strategic agreement with Siemens Healthineers. - https://biognosys.com/news/biognosys-announces-strategic-agreement-with-siemens-healthineers/
- RubrYc Therapeutics announces a research collaboration and licensing option agreement with zai labs. - https://www.rubryc.com/news/rubryc-therapeutics-announces-research-collaboration-and-license-option-agreement-zai-labs
- TILT Biotherapeutics and MSD to collaborate on clinical trial of adenoviral cancer immunotherapeutic TILT-123 in combination with Keytruda® (pembrolizumab) for ovarian cancer. - https://tiltbio.com/news-events/
- Boehringer Ingelheim and MD Anderson expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer. - https://www.boehringer-ingelheim.com/press-release/expanded-collaboration-md-anderson
- ROSALIND, HELiXrUS and Geninus partner to bring powerful new single cell analysis services to cancer researchers. - https://www.businesswire.com/news/home/20210415005348/en
- Amgen and Neogenomics partner to expand biomarker testing access in NSCLC. - https://www.amgen.com/newsroom/press-releases/2021/04/amgen-launches-biomarker-assist-a-program-to-help-more-patients-with-nonsmall-cell-lung-cancer-gain-access-to-biomarker-testing
- Astrazeneca, Loxo Oncology at Lilly, and Invitae Corporation join the access to comprehensive genomic profiling coalition. - https://www.prnewswire.com/news-releases/astrazeneca-loxo-oncology-at-lilly-and-invitae-corporation-join-the-access-to-comprehensive-genomic-profiling-coalition-301270830.html?tc=eml_cleartime
- Northshore and Sema4 launch system-wide genomics program to improve primary and specialty care with data-driven insights. - https://sema4.com/news/northshore-and-sema4-partnership/
- Kaiku Health joins forces with Novartis for melanoma monitoring and support. - https://www.mobihealthnews.com/news/kaiku-health-joins-forces-novartis-melanoma-monitoring-and-support
- Illumina and Kartos Therapeutics announce new oncology partnership to develop an NGS-based TP53 companion diagnostic. - https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=12b6e4a6-3f52-407e-8200-8fa72712a980
- The Aptorum Group enters into a material transfer and exclusive option license rights agreement with Yale University for its novel immunomodulators with the potential to target autoimmune and oncological diseases. - https://ir.aptorumgroup.com/news-releases/news-release-details/aptorum-group-enters-material-transfer-and-exclusive-option
- Paige and Leica Biosystems partner to expand access to computational pathology products for pathology and oncology research. - https://www.paige.ai/resources/paige-and-leica-biosystems-partner-to-expand-access
- Pieris Pharmaceuticals and Boston Pharmaceuticals enter into an exclusive worldwide product license for PRS-342, a 4-1BB/GPC3 immuno-oncology bispecific. - https://www.pieris.com/news-and-events/press-releases/detail/658/pieris-pharmaceuticals-and-boston-pharmaceuticals-enter
- Guardant Health announces collaboration with Daiichi Sankyo to develop Guardant360® CDx as a companion diagnostic for Enhertu® in advanced metastatic non-small cell lung cancer. - https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant-Health-Announces-Collaboration-With-Daiichi-Sankyo-to-Develop-Guardant360-CDx-as-a-Companion-Diagnostic-for-Enhertu-in-Advanced-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspx
- Castle Biosciences signs definitive agreement to acquire Myriad myPath® Laboratory. - https://ir.castlebiosciences.com/news-releases/news-release-details/castle-biosciences-signs-definitive-agreement-acquire-myriad
- BostonGene and the Medical College of Wisconsin announce research collaboration. - https://bostongene.com/bostongene-and-the-medical-college-of-wisconsin-announce-research-collaboration/
- Mirum Pharmaceuticals and CANbridge pharmaceuticals enter into exclusive licensing agreement to develop and commercialize maralixibat in greater China for rare liver diseases. - https://ir.mirumpharma.com/news-releases/news-release-details/mirum-pharmaceuticals-and-canbridge-pharmaceuticals-enter
Giovanni Dothel, PhD - gdothel@ipbadvisors.com - Inflection Point Biomedical Advisors
Jaume Calafell - jcalafell@ipbadvisors.com - Inflection Point Biomedical Advisors